SCHEMBL7740145

SCHEMBL7740145

CC(C)(C)OC(=O)C(N)CCC(=O)OCc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 3/20 0.61
ALDH1A1 P00352 3/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
SLC15A1 P46059 2/20 0.45
SYK P43405 1/20 0.44
LMNA P02545 1/20 0.43
MEN1 O00255 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42
SLC7A5 Q01650 1/20 0.42
POLB P06746 1/20 0.41
PSMB5 P28074 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7740147 1.00 LTA4H (0.61) LTA4HALDH1A1MAPK1L3MBTL1SLC15A1
SCHEMBL12155266 1.00 LTA4H (0.61) LTA4HALDH1A1MAPK1L3MBTL1SLC15A1
Hydrochloric Acid SCHEMBL15387431 0.99 LTA4H (0.60) LTA4HALDH1A1MAPK1L3MBTL1SLC15A1
Hydrochloric Acid SCHEMBL3501117 0.99 LTA4H (0.60) LTA4HALDH1A1MAPK1L3MBTL1SLC15A1
Hydrochloric Acid SCHEMBL25286512 0.99 LTA4H (0.60) LTA4HALDH1A1MAPK1L3MBTL1SLC15A1
SCHEMBL8698981 0.92 LTA4H (0.56) LTA4HALDH1A1MAPK1L3MBTL1SLC15A1
SCHEMBL28119342 0.90 LTA4H (0.52) LTA4HALDH1A1MAPK1L3MBTL1SLC15A1
SCHEMBL28119343 0.90 LTA4H (0.52) LTA4HALDH1A1MAPK1L3MBTL1SLC15A1
SCHEMBL22911218 0.89 LTA4H (0.56) LTA4HALDH1A1MAPK1L3MBTL1SLC15A1
SCHEMBL14450594 0.89 LTA4H (0.56) LTA4HALDH1A1MAPK1L3MBTL1SLC15A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105541649-A Preparation method of glutamic acid-5-benzyl ester-1-tert-butyl ester hydrochloride GL BIOCHEM (SHANGHAI) LTD 2016-05-04 CN claimed
CN-113677400-B Dual mode radiotracer and therapeutic agent that bind PSMA 慕尼黑工业大学 2023-12-01 CN disclosed
CN-116675730-A Dual mode radiotracer and therapeutic agent that bind PSMA 慕尼黑工业大学 2023-09-01 CN disclosed
EP-3127604-B1 PROCESS FOR THE PREPARATION OF LYSIN-GLUTAMIC ACID DIPEPTIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2018-08-22 EP disclosed
US-20180099934-A1 PSMA-TARGETED NIR DYES AND THEIR USES On Target Laboratories, Inc. 2018-04-12 US disclosed
US-20180029978-A1 PROCESS FOR MAKING LYSINE-GLUTAMIC ACID DIPEPTIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-02-01 US disclosed
US-9802886-B2 Process for making lysine-glutamic acid dipeptide derivatives HOFFMANN-LA ROCHE INC. (US) 2017-10-31 US disclosed
EP-2849882-B1 LYSIN-GLUTAMIC ACID DIPEPTIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2017-06-14 EP disclosed
US-20170057912-A1 PROCESS FOR MAKING LYSINE-GLUTAMIC ACID DIPEPTIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-03-02 US disclosed
EP-3127604-A1 LYSIN-GLUTAMIC ACID DIPEPTIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2017-02-08 EP disclosed
CN-104271227-A Lysin-glutamic acid dipeptide derivatives HOFFMANN LA ROCHE 2015-01-07 CN disclosed
WO-2013171135-A1 LYSIN-GLUTAMIC ACID DIPEPTIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-11-21 WO disclosed
EP-2664374-A1 Lysin-glutamic acid dipeptide derivatives F. Hoffmann-La Roche AG (CH) 2013-11-20 EP disclosed
US-7888348-B2 7-membered ring compound and method of production and pharmaceutical application thereof DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-02-15 US disclosed
US-7888348-B2 7-membered ring compound and method of production and pharmaceutical application thereof DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-02-15 US disclosed
US-20090111796-A1 7-membered ring compound and method of production and pharmaceutical application thereof DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-04-30 US disclosed
US-20090111796-A1 7-membered ring compound and method of production and pharmaceutical application thereof DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-04-30 US disclosed
US-6420427-B1 PREVENTION AND/OR TREATMENT OF RHEUMATOID DISEASES, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS, INTERSTITIAL NEPHRITIS, ARTERIOSCLEROSIS, PULMONARY EMPHYSEMA, CIRRHOSIS, CORNEA INJURY ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
EP-1024134-A1 AMINOBUTANOIC ACID DERIVATIVES ONO PHARMACEUTICAL CO., LTD. (JP) 2000-08-02 EP disclosed
US-5919769-A ANTIINFLAMMATORY AGENT KANEBO, LTD (JP) 1999-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099934-A1 PSMA-TARGETED NIR DYES AND THEIR USES FOLH1, KLK3, PSMA6 LTA4H 3263/4885ALDH1A1 477/4885MAPK1 4730/4885
US-20090111796-A1 7-membered ring compound and method of production and pharmaceutical application thereof CMA1, CPA3, SI LTA4H 219/4885ALDH1A1 1889/4885MAPK1 3456/4885
US-20180029978-A1 PROCESS FOR MAKING LYSINE-GLUTAMIC ACID DIPEPTIDE DERIVATIVES GLUL, ASNS, QPCT LTA4H 475/4885ALDH1A1 2242/4885MAPK1 1610/4885
US-20170057912-A1 PROCESS FOR MAKING LYSINE-GLUTAMIC ACID DIPEPTIDE DERIVATIVES GLUL, ASNS, QPCT LTA4H 475/4885ALDH1A1 2242/4885MAPK1 1610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.